Copyright
©14 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 21, 2014; 20(43): 15992-16013
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.15992
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.15992
Figure 1 Hepatitis C virus genome and nucleotide variability.
A schematic representation of the viral genome is depicted. The degree of nucleotide variability along the viral genome is also shown. The target molecules for anti-HCV therapy are noted, and the antiviral agents are indicated. A selection of FDA approved and in development compounds are shown. Roman numerals in brackets indicate the current clinical phase of development. HCV: Hepatitis C virus; FDA: Food and Drug Administration; PI: Protease inhibitors.
- Citation: Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, Vazquez-Chacon C, Martinez-Guarneros A, Carpio-Pedroza JC, Fonseca-Coronado S, Cruz-Rivera M. Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World J Gastroenterol 2014; 20(43): 15992-16013
- URL: https://www.wjgnet.com/1007-9327/full/v20/i43/15992.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i43.15992